nMet, a new target in recurrent cancer

Yingqiu Xie, Sholpan Istayeva, Zhanlin Chen, Tursonjan Tokay, Zhaxybay Zhumadilov, Denglong Wu, Gonzalo Hortelano, Jinfu Zhang

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-dependent (full length Met) and -independent (cleaved Met) manner. nMET may play greater essential roles in cancer recurrence than membranous Met. For example, in prostate cancer, it has been found that androgen receptor (AR) may inhibit the expression of membranous Met so anti-androgen based prostate cancer therapy may promote the expression of nuclear Met (nMET). We recently found a novel nMET/SOX9/ β-Catenin/AR pathway in relapsed prostate cancer which may contribute to the formation of the feedback loop of AR reactivation via MET/nMET. Emerging evidence suggests the possibility of nMET as a prognostic marker in relapsed cancer. This review summarizes recent findings about nMET and its unique role in recurrent cancer.

Original languageEnglish
Pages (from-to)572-578
Number of pages7
JournalCurrent Cancer Drug Targets
Volume16
Issue number7
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Neoplasms
Catenins
Androgens
Neoplasm Metastasis
Ligands
Recurrence
Growth
Therapeutics

Keywords

  • Met
  • Nuclear translocation
  • Oncogene
  • Recurrence

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

nMet, a new target in recurrent cancer. / Xie, Yingqiu; Istayeva, Sholpan; Chen, Zhanlin; Tokay, Tursonjan; Zhumadilov, Zhaxybay; Wu, Denglong; Hortelano, Gonzalo; Zhang, Jinfu.

In: Current Cancer Drug Targets, Vol. 16, No. 7, 01.09.2016, p. 572-578.

Research output: Contribution to journalReview article

Xie, Yingqiu ; Istayeva, Sholpan ; Chen, Zhanlin ; Tokay, Tursonjan ; Zhumadilov, Zhaxybay ; Wu, Denglong ; Hortelano, Gonzalo ; Zhang, Jinfu. / nMet, a new target in recurrent cancer. In: Current Cancer Drug Targets. 2016 ; Vol. 16, No. 7. pp. 572-578.
@article{74fae340e04d4bc0ac0ddba14ce6423f,
title = "nMet, a new target in recurrent cancer",
abstract = "Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-dependent (full length Met) and -independent (cleaved Met) manner. nMET may play greater essential roles in cancer recurrence than membranous Met. For example, in prostate cancer, it has been found that androgen receptor (AR) may inhibit the expression of membranous Met so anti-androgen based prostate cancer therapy may promote the expression of nuclear Met (nMET). We recently found a novel nMET/SOX9/ β-Catenin/AR pathway in relapsed prostate cancer which may contribute to the formation of the feedback loop of AR reactivation via MET/nMET. Emerging evidence suggests the possibility of nMET as a prognostic marker in relapsed cancer. This review summarizes recent findings about nMET and its unique role in recurrent cancer.",
keywords = "Met, Nuclear translocation, Oncogene, Recurrence",
author = "Yingqiu Xie and Sholpan Istayeva and Zhanlin Chen and Tursonjan Tokay and Zhaxybay Zhumadilov and Denglong Wu and Gonzalo Hortelano and Jinfu Zhang",
year = "2016",
month = "9",
day = "1",
doi = "10.2174/1568009616666160105105250",
language = "English",
volume = "16",
pages = "572--578",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers",
number = "7",

}

TY - JOUR

T1 - nMet, a new target in recurrent cancer

AU - Xie, Yingqiu

AU - Istayeva, Sholpan

AU - Chen, Zhanlin

AU - Tokay, Tursonjan

AU - Zhumadilov, Zhaxybay

AU - Wu, Denglong

AU - Hortelano, Gonzalo

AU - Zhang, Jinfu

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-dependent (full length Met) and -independent (cleaved Met) manner. nMET may play greater essential roles in cancer recurrence than membranous Met. For example, in prostate cancer, it has been found that androgen receptor (AR) may inhibit the expression of membranous Met so anti-androgen based prostate cancer therapy may promote the expression of nuclear Met (nMET). We recently found a novel nMET/SOX9/ β-Catenin/AR pathway in relapsed prostate cancer which may contribute to the formation of the feedback loop of AR reactivation via MET/nMET. Emerging evidence suggests the possibility of nMET as a prognostic marker in relapsed cancer. This review summarizes recent findings about nMET and its unique role in recurrent cancer.

AB - Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-dependent (full length Met) and -independent (cleaved Met) manner. nMET may play greater essential roles in cancer recurrence than membranous Met. For example, in prostate cancer, it has been found that androgen receptor (AR) may inhibit the expression of membranous Met so anti-androgen based prostate cancer therapy may promote the expression of nuclear Met (nMET). We recently found a novel nMET/SOX9/ β-Catenin/AR pathway in relapsed prostate cancer which may contribute to the formation of the feedback loop of AR reactivation via MET/nMET. Emerging evidence suggests the possibility of nMET as a prognostic marker in relapsed cancer. This review summarizes recent findings about nMET and its unique role in recurrent cancer.

KW - Met

KW - Nuclear translocation

KW - Oncogene

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84986888464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986888464&partnerID=8YFLogxK

U2 - 10.2174/1568009616666160105105250

DO - 10.2174/1568009616666160105105250

M3 - Review article

C2 - 26728040

AN - SCOPUS:84986888464

VL - 16

SP - 572

EP - 578

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 7

ER -